AstraZeneca touts extended safety and efficacy data on Fasenra; Vanessa King takes the helm at Virion
→ AstraZeneca $AZN has rolled out a new round of safety and efficacy data they’ve been gathering from an extension study of Fasenra (benralizumab), their new drug for severe eosinophilic asthma. Researchers say they tracked an excellent safety profile at 56 weeks, adding: “74% of patients with a baseline blood eosinophil count of 300 cells per μL or greater (the primary efficacy population in the Phase III trials) who received FASENRA every eight weeks continuously from SIROCCO or CALIMA and into BORA, were exacerbation-free in BORA in their second year of treatment and maintained improvements in lung function and asthma control.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.